Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Phase II AK Study in Organ Transplant Patients
Scientific title
A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Actinic Keratoses 0 0
Carcinoma, Squamous Cell 0 0
Organ Transplant Recipients 0 0
Condition category
Condition code
Skin 0 0 0 0
Other skin conditions
Cancer 0 0 0 0
Non melanoma skin cancer
Skin 0 0 0 0
Dermatological conditions

Study type
Description of intervention(s) / exposure
Treatment: Drugs - Afamelanotide (CUV1647)
Treatment: Drugs - Placebo

Experimental: 1 - Afamelanotide (CUV1647) implant administered subcutaneously every 60 days for 24 months

Placebo Comparator: 2 - Placebo implant administered subcutaneously every 60 days for 24 months

Treatment: Drugs: Afamelanotide (CUV1647)
16 mg subcutaneous implant administered every 60 days

Treatment: Drugs: Placebo
Placebo subcutaneous implant administered every 60 days

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
To determine the effect of afamelanotide (CUV1647) administered from slow release subcutaneous implants on the number of actinic keratoses (AKs) on the head, forearms and back of hands
Timepoint [1] 0 0
24 months
Secondary outcome [1] 0 0
To determine and compare the proportion of patients in each group that develops one or more squamous cell carcinoma (SCC)
Timepoint [1] 0 0
24 months
Secondary outcome [2] 0 0
To examine the effect of ongoing sun exposure on lesion formation and progression in the patient group
Timepoint [2] 0 0
24 months
Secondary outcome [3] 0 0
To evaluate the safety and tolerability of multiple slow release subcutaneous implants of afamelanotide (CUV1647)
Timepoint [3] 0 0
24 months

Key inclusion criteria
- Organ transplant recipients with stable transplant function and who received their
transplant at least 2 years prior to study entry

- Organ transplant patients who have had at least one biopsy-positive SCC

- Aged 18 - 75 years

- Written informed consent to the performance of all study-specific procedures
Minimum age
18 Years
Maximum age
75 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Allergy to afamelanotide (CUV1647) or the polymer contained in the implant

- History of melanoma

- Current pigmentary disorders such as melasma

- Diagnosed with HIV/AIDS, or hepatitis B or C

- Current history of drug or alcohol abuse (in the last 12 months)

- Clinically significant organ dysfunction, history of medical disorders or other
factors, which in the opinion of the investigator will interfere with the
interpretation of study outcome measures

- Major medical or psychiatric illness

- Pregnancy as confirmed by positive serum beta-HCG pregnancy test prior to baseline or
lactating mothers

- Females of child bearing potential not using adequate contraceptive measures

- Participation in a clinical trial for an investigational agent within 30 days prior to
the screening visit

- Use of regular medications or any other factors that may affect skin pigmentation

Discontinuation Criteria:

- Initiation of treatment with systemic retinoids

- Change of class of systemic immunosuppressant treatment

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people analysing the results/data
Intervention assignment
Other design features
Phase 2
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Unknown status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
The Princess Alexandra Hospital - Brisbane
Recruitment hospital [2] 0 0
The Queen Elizabeth Hospital - Adelaide
Recruitment hospital [3] 0 0
The Royal Melbourne Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
4102 - Brisbane
Recruitment postcode(s) [2] 0 0
5011 - Adelaide
Recruitment postcode(s) [3] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
State/province [1] 0 0
Country [2] 0 0
State/province [2] 0 0
Country [3] 0 0
State/province [3] 0 0
Country [4] 0 0
State/province [4] 0 0
Country [5] 0 0
State/province [5] 0 0
Country [6] 0 0
State/province [6] 0 0
Country [7] 0 0
State/province [7] 0 0
Country [8] 0 0
State/province [8] 0 0
Country [9] 0 0
State/province [9] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Clinuvel Pharmaceuticals Limited

Ethics approval
Ethics application status

Brief summary
The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in
reducing the number of actinic keratoses and squamous cell carcinomas developing in immune
compromised organ transplant recipients, who are at particularly high risk, over a 24 month
test period.

The number of lesions formed on the head, hands and forarms will be monitored over this 24
month test period.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Günther Hofbauer, M.D.
Address 0 0
Universitätsspital Zürich
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see